.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
McKesson
Colorcon
Express Scripts
Teva
Julphar
US Department of Justice
QuintilesIMS
Boehringer Ingelheim
US Army

Generated: December 18, 2017

DrugPatentWatch Database Preview

Perrigo New York Company Profile

« Back to Dashboard

What is the competitive landscape for PERRIGO NEW YORK, and when can generic versions of PERRIGO NEW YORK drugs launch?

PERRIGO NEW YORK has sixty-one approved drugs.

There is one US patent protecting PERRIGO NEW YORK drugs.

There are five patent family members on PERRIGO NEW YORK drugs in five countries and seventeen supplementary protection certificates in nine countries.

Summary for Perrigo New York

International Patents:5
US Patents:1
Tradenames:30
Ingredients:29
NDAs:61
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo New YorkHYDROCORTISONEhydrocortisoneOINTMENT;TOPICAL085027-001Approved Prior to Jan 1, 1982ATRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo New YorkDESONIDEdesonideOINTMENT;TOPICAL017426-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Perrigo New YorkHYDROCORTISONE VALERATEhydrocortisone valerateCREAM;TOPICAL075666-001May 24, 2000ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo New YorkNYSTATIN AND TRIAMCINOLONE ACETONIDEnystatin; triamcinolone acetonideCREAM;TOPICAL062186-002Jun 6, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New YorkTERCONAZOLEterconazoleSUPPOSITORY;VAGINAL077149-001Mar 17, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo New YorkNYSTATIN AND TRIAMCINOLONE ACETONIDEnystatin; triamcinolone acetonideOINTMENT;TOPICAL062280-002Oct 10, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New YorkHYDROCORTISONEhydrocortisoneLOTION;TOPICAL085662-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New YorkFLUOCINOLONE ACETONIDEfluocinolone acetonideCREAM;TOPICAL086810-001Mar 4, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New YorkTRIAMCINOLONE ACETONIDEtriamcinolone acetonideOINTMENT;TOPICAL087385-001Approved Prior to Jan 1, 1982ATRXNoYes► Subscribe► Subscribe► Subscribe
Perrigo New YorkMINOXIDIL EXTRA STRENGTH (FOR MEN)minoxidilSOLUTION;TOPICAL075737-001Mar 15, 2002OTCNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Perrigo New York Drugs

Country Document Number Estimated Expiration
Spain2165723► Subscribe
Canada2259764► Subscribe
European Patent Office0933081► Subscribe
Israel123143► Subscribe
Germany69900561► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Perrigo New York Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00617Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
C/GB97/005United Kingdom► SubscribePRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926
C0014France► SubscribePRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
80024Netherlands► SubscribePRODUCT NAME: GADOBEENZUUR,DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN ALKA- LIMETAAL, AARDALKALIMETAAL, OF BASISCH GEPROTONEERD AMINOZUUR OF VAN EEN ALKYLAMMONIUM-, ALKANOLAMMONIUM- OF POLYHYDROXYAL- KYLAMMONIUMZOUT, IN HET BIJZONDER DIMEGLUMINI GADOBENAS; NAT. REGISTRATION NO/DATE: RVG 22324 19980706; FIRST REGISTRATION: GB PL 06099/0006 19970722
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
60031Netherlands► SubscribePRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1304992/01Switzerland► SubscribePRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Fish and Richardson
McKesson
Cipla
Fuji
Daiichi Sankyo
Covington
Cantor Fitzgerald
QuintilesIMS
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot